# Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

> **NCT03874052** · PHASE1 · RECRUITING · sponsor: **Jennifer Saultz** · enrollment: 51 (estimated)

## Conditions studied

- Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
- Recurrent Acute Myeloid Leukemia
- Recurrent Secondary Acute Myeloid Leukemia
- Refractory Acute Myeloid Leukemia
- Refractory Secondary Acute Myeloid Leukemia

## Interventions

- **DRUG:** Azacitidine
- **PROCEDURE:** Biospecimen Collection
- **PROCEDURE:** Bone Marrow Aspiration
- **PROCEDURE:** Bone Marrow Biopsy
- **PROCEDURE:** Echocardiography Test
- **PROCEDURE:** Punch Biopsy
- **OTHER:** Questionnaire Administration
- **DRUG:** Ruxolitinib
- **DRUG:** Venetoclax

## Key facts

- **NCT ID:** NCT03874052
- **Lead sponsor:** Jennifer Saultz
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2019-08-16
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-03-24

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03874052

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03874052, "Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03874052. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*